Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Valsartan solid dispersion and preparation method thereof

A technology of solid dispersion and valsartan, which is applied in the field of medicine, can solve the problems of low drug solubility, achieve the effect of improving the dissolution rate and solving the problem of organic solvent residue

Inactive Publication Date: 2012-02-22
SUZHOU UNIV
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] Although the dispersible tablet of the above-mentioned patent has a certain effect on improving the drug compliance of patients and improving the dissolution rate and bioavailability of the drug, this dosage form still cannot effectively solve the problem of low drug solubility.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Valsartan solid dispersion and preparation method thereof
  • Valsartan solid dispersion and preparation method thereof
  • Valsartan solid dispersion and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment one: the preparation of valsartan solid dispersion

[0038] Put 800mg of valsartan and 2400mg of polyethylene glycol 6000 melted in a water bath at 50-60°C in a beaker, add 5ml of 0.8mol / L sodium hydroxide solution and stir, and add an appropriate amount of distilled water and stir until the valsartan and high The molecules are all dissolved in water to form a clear solution, which is freeze-dried until the sample is completely dried to form a solid dispersion.

Embodiment 2

[0039] Embodiment two: the preparation of valsartan solid dispersion

[0040]Put 800mg valsartan and 2400mg polyvinylpyrrolidone K-30 in a beaker, add 5ml of 0.8mol / L sodium hydroxide solution to stir, and add appropriate amount of distilled water to stir until both valsartan and polymer are dissolved in water to form Clarify the solution and freeze-dry until the sample is completely dry to form a solid dispersion.

Embodiment 3

[0041] Embodiment three: the preparation of valsartan solid dispersion

[0042] Put 800mg valsartan and 2400mg hypromellose in a beaker, add 5ml of 0.8mol / L sodium hydroxide solution to stir, and add appropriate amount of distilled water to stir until valsartan and polymer are dissolved in water to form a clear The solution was freeze-dried until the sample was completely dried to form a solid dispersion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, particularly a valsartan solid dispersion and a preparation method thereof. The valsartan solid dispersion comprises a pharmaceutical valsartan, a carrier and an alkaline matter, and can also comprises a surfactant, wherein the carrier is a hydrophilic high-polymer carrier, and the mass ratio of pharmaceutical valsartan:hydrophilic high-polymer carrier:alkaline matter:surfactant is 1:(2-4):(0.1-0.3):(0.1-0.2). The valsartan solid dispersion has favorable leaching rate in use, and can be conveniently absorbed by the gastrointestinal tract, thereby improving the bioavailability.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a solid dispersion of valsartan, a specific angiotensin II receptor (AT1 type) antagonist, and a preparation method thereof. Background technique [0002] Hypertension is the most common type of cardiovascular and cerebrovascular diseases. About 972 million people worldwide suffer from high blood pressure or high blood pressure. Equivalent to 26.4% of the adult population. The prevalence of hypertension among adults in my country has risen to 18.8%. The number of sick people nationwide has reached 160 million. It has become a social problem that cannot be ignored. Angiotensin II (Ang II) receptor antagonists are another class of antihypertensive drugs after angiotensin-converting enzyme (ACE) inhibitors. Compared with ACE inhibitors, these drugs directly act on receptors and avoid ACE has the disadvantages of inhibition, safe and reliable antihypertensive effect, and few si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K9/19A61K31/41A61K47/34A61K47/32A61K47/36A61P9/12
Inventor 曹青日徐卫娟崔京浩
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com